Roche’s Crovalimab receives Orphan Drug Designation in KOR
By Eo, Yun-Ho | translator Kim, Jung-Ju
24.02.01 17:43:50
가나다라
0
demonstrates noninferiority to Soliris through head-to-head trial
Competition intensifies in PNH treatment market… Novartis and other companies join in the competition
The Ministry of Food and Drug Safety (MFDS) announced so through an orphan drug designation notice on the 1st.
Crovalimab, which was discovered by Japanese drugmaker Chugai Pharmaceutical and developed by Roche, is a treatment for paroxysmal nocturnal hemoglobinuria (PNH) that is currently undergoing approval processes in the United States, Europe, and Japan.
Crovalimab is a novel C5 inhibitor that is recycled within the bloodstream, enabling sustained complement inhibition through low-dose, subcutaneous (SC) administration every 4 weeks.
The drug’s potential was confirm
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)